Exsure

Exsure is an Indian biotechnology startup focused on advancing precision medicine through exosome-based drug delivery technologies and cancer research. Headquartered in Bhubaneswar, Odisha, with an R&D unit in Pune, the company is dedicated to developing innovative solutions that improve the effectiveness of cancer treatment while minimizing the harmful side effects of conventional chemotherapy. Exsure's mission is to democratize access to high-quality and affordable cancer therapy by leveraging the therapeutic potential of exosomes—naturally occurring extracellular vesicles that can transport drugs and biological molecules directly to diseased cells. The company aims to create targeted therapies that selectively attack cancer stem cells, which are considered the primary cause of tumor recurrence and treatment resistance, while preserving healthy tissues. At the core of Exsure's research is India's first patented exosome-based targeted anti-cancer drug delivery platform. By engineering exosomes as natural nanocarriers, the company seeks to deliver therapeutic agents directly to cancer cells with greater precision than conventional chemotherapy. This targeted approach has the potential to reduce chemo-induced toxicity, improve relapse-free survival, enhance treatment outcomes, and significantly improve patients' quality of life. In addition to its therapeutic research, Exsure develops research reagents and biotechnology products that support exosome isolation, characterization, and cancer stem cell studies. Its flagship products include EXOSURE, India's first 2-in-1 exosome isolation reagent, along with LEUCOSURE for lymphocyte isolation and PlantEXOSURE for plant-derived exosome isolation. These products are designed to support researchers, biotechnology companies, and academic institutions working in regenerative medicine, molecular biology, oncology, and extracellular vesicle research. Beyond product development, Exsure provides specialized research services, including cancer stem cell isolation, characterization, tissue-derived stem cell banking, exosome isolation, bioengineered exosome generation, and grant-writing support for scientific projects. The company collaborates with research institutions, healthcare organizations, and biotechnology partners to accelerate the translation of laboratory discoveries into practical medical applications. Exsure has gained recognition within India's startup ecosystem through achievements such as receiving the Startup India Seed Fund, being recognized among the Top 100 Leap to Unicorn startups, securing a place among Odisha's top emerging startups, and attracting investment from venture capital firms. Its membership in the Indian Extracellular Vesicles Society further reflects its commitment to advancing exosome science and innovation. With a strong emphasis on indigenous biotechnology, scientific excellence, and affordable healthcare solutions, Exsure is positioning itself as a key contributor to India's growing life sciences sector while working toward next-generation targeted therapies that have the potential to transform cancer treatment and precision medicine globally